On April 2nd, the White House signed a proclamation imposing new tariffs on patented pharmaceutical products under Section 232 of the Trade Expansion Act of 1962, the same national security trade authority underlying longstanding tariffs on steel and aluminum. The headline rate is 100%. But for health plans and TPAs managing specialty drug costs, that number requires context before it becomes useful for strategic rebate management and financial planning.
This post breaks down what the proclamation actually says, what’s still in flux, and what the current environment reveals about cost management readiness heading into the second half of 2026.
What the Proclamation Actually Says — and What It Doesn’t Settle
The April 2nd action followed a formal Commerce Department national security investigation into pharmaceutical imports, a process that gives these tariffs more structural durability than many of the trade actions that preceded them. When the Supreme Court struck down IEEPA-based tariffs in February 2026, Section 232 tariffs were explicitly preserved. That legal distinction matters for organizations trying to assess how seriously to treat this development.
At the same time, the proclamation is explicitly designed around deal-making. Thirteen major manufacturers had already entered qualifying agreements before the proclamation was signed, and companies that sign most-favored-nation pricing agreements with HHS while committing to domestic manufacturing are exempt. The rates vary further by country of origin, 15% for products from the EU, Japan, Korea, and Switzerland; 10% for the UK, and more negotiations are underway.
Effective dates are July 31, 2026 for large companies and September 29, 2026 for others. How the cost picture actually looks, drug by drug, will continue to develop between now and then.
The takeaway: this is a real policy development grounded in legitimate legal authority, but the final scope of impact is still being negotiated in real time.
The Structural Split Worth Understanding
One element of the proclamation is clear and unlikely to shift significantly: generic pharmaceuticals, biosimilars, and their associated ingredients are expressly excluded from Section 232 tariffs at this time, though that exemption is subject to review within one year.
That carve-out creates a meaningful divergence for cost management purposes. The drugs currently in scope for tariff consideration are patented, brand-name specialty products, which are also the category where manufacturer rebate programs exist. Generics and biosimilars, which carry little to no rebate value, sit outside the tariff framework for now.
For health plans and TPAs managing specialty drug spend under the medical benefit, that alignment is worth noting. The policy pressure and the available financial offsets, manufacturer rebates on patented specialty drugs, are pointed at the same category. Organizations that aren’t capturing those rebates on the medical benefit side are already absorbing cost exposure without one of the few offsets available to them, and that gap becomes more visible in an environment where input costs are under pressure.
Implications for Health Plans and TPAs
For health plans managing Part B and Part C populations, the tariff environment adds another layer of uncertainty to patented specialty drug cost modeling. Actuarial assumptions, benefit design decisions, and trend projections built on prior-year unit costs may need to be stress-tested before mid-year. The more durable question isn’t the specific tariff rate — it’s whether current net cost reporting is clean enough to support planning decisions as input cost assumptions shift.
For TPAs and self-funded employers, the immediate implication is similar: specialty drug cost conversations with clients are becoming more complex. TPAs that can explain pharmacy rebate performance but have no equivalent visibility or process on the medical benefit side are navigating that complexity with an incomplete picture. Patented specialty drugs administered in clinical settings, infused biologics, oncology agents, and high-cost physician-administered therapies are exactly the drugs in scope for both tariff consideration and medical benefit rebate recovery.
What to Watch on Strategic Rebate Management
As the tariff environment continues to develop, a few watchpoints are worth tracking from a strategic rebate management perspective.
Company-level deal activity before the effective dates. More manufacturers are likely to reach agreements with the administration before July 31st. The practical tariff exposure for any given drug will depend significantly on whether its manufacturer reaches a qualifying deal, making product-level tracking more important than headline rate monitoring.
The biosimilar and generics exemption carries a review window. The proclamation directs a formal review of the exemption within one year. Organizations making formulary or benefit design decisions based on current biosimilar exemption status should factor that timeline into longer-range planning assumptions.
Net cost assumptions deserve a fresh look. Not because costs have definitively changed, but because the range of possible outcomes has widened. Budget projections for patented specialty drugs built on prior-year unit costs carry more uncertainty today than they did six months ago.
The medical benefit remains the less-managed side. Whatever pricing dynamics emerge on patented specialty drugs, the rebate capture infrastructure for those drugs under the medical benefit significantly lags the pharmacy side for many mid-market plans and TPAs. That gap predates this tariff environment and will persist beyond it — but the current environment makes it harder to ignore.
The Planning Takeaway
The April 2nd proclamation doesn’t settle the cost picture for patented specialty drugs. It adds a layer of pricing uncertainty to a category already under pressure from multiple directions, IRA negotiation dynamics, biosimilar competition, reimbursement pressures, and now a tariff framework still taking shape.
The most useful near-term response isn’t to react to a number that may not apply to the drugs most relevant to your organization. It’s to assess whether the financial infrastructure around those drugs, net cost visibility, rebate capture, and documentation, is strong enough to support decisions in an environment where inputs are less predictable than they were.
Pharmacy leaders and CFOs should monitor the Commerce Department’s Section 232 findings, supplier earnings guidance, and contract language tied to tariff contingencies. That’s sound operational advice regardless of where individual drug-level tariff rates ultimately land.
For organizations where strategic rebate management on the medical benefit side hasn’t been built out, the tariff environment is a prompt worth acting on, not because the 100% rate is certain, but because cost pressure on patented specialty drugs is coming from enough directions that every available offset deserves to be working.
How is your organization approaching specialty drug cost planning heading into the second half of 2026? Leave a comment below, we’ll compile themes and return to this topic as the policy picture becomes clearer.
Disclaimer: This post is provided by VativoRx for informational and educational purposes only and does not constitute legal, regulatory, clinical, or financial advice. VativoRx is not affiliated with any government agency or program referenced. Tariff policy details are evolving and subject to change; the information above reflects publicly available sources as of the date of publication. Readers should consult their legal, trade, and financial advisors regarding specific circumstances.
